Skip to main content

Valamehr Bahram's Form 4 filing

Fate Therapeutics Inc (FATE) · filed Jul 8, 2022

Accession no.
0001209191-22-041670
Filed
Jul 8, 2022
Trade date
Jul 7, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $518.7K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Valamehr BahramCIK 0001748177Officer (Chief R&D Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 7, 2022Common StockMOption exerciseAcquired+17,158$2.73+$46,841.34196,992Direct
Jul 7, 2022Common StockSSaleDisposed−17,158$30.23−$518,686.34179,834Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 7, 2022Common StockMOption exerciseDisposed−17,158$2.73−$46,841.3413,156Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)